WC
ALNY icon

Wexford Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Wexford Capital’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-5,250
Closed -$491K – 114
2019
Q1 		$491K Sell
5,250
-5,000
-49% -$418K 0.04% 80
2018
Q4 		$747K Sell
10,250
-6,000
-37% -$461K 0.06% 59
2018
Q3 		$1.42M Hold
16,250
– – 0.09% 95
2018
Q2 		$1.6M Hold
16,250
– – 0.1% 76
2018
Q1 		$1.94M Buy
+16,250
New +$2.09M 0.14% 59
2017
Q3 		– Sell
-4,300
Closed -$343K – 144
2017
Q2 		$343K Buy
+4,300
New +$275K 0.03% 144

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Wexford Capital's ALNY Position: Q2 2019 in Review

Wexford Capital sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2019, closing a stake of 5,250 shares — an estimated $491K sold.

Wexford Capital first reported a position in ALNY in Q2 2017 and held it in 6 quarters. The position peaked at $1.94M in Q1 2018. 290 funds tracked by Wall St. Rank hold ALNY as of Q2 2019.

  • Wexford Capital reported no remaining Alnylam Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Wexford Capital sold 5,250 Alnylam Pharmaceuticals shares in Q2 2019, an estimated $491K.
  • Wexford Capital first reported a position in Alnylam Pharmaceuticals in Q2 2017 and held it in 6 quarters.
  • Wexford Capital's Alnylam Pharmaceuticals position peaked at $1.94M in Q1 2018.
  • 290 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2019.

Based on Wexford Capital's 13F filing for Q2 2019, filed 14 Aug 2019.